Here we investigated the efficacy of the survivin suppressant YM155 in a panel of neuroblastoma cell lines consisting of the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN)-amplified neuroblastoma cell lines UKF-NB-3 und UKF-NB-6 and their sublines with acquired resistance to cisplatin (UKF-NB-3rCDDP1000), doxorubicin (UKF-NB-6rDOX20), and vincristine (UKF-NB-3rVCR10 and UKF-NB-6rVCR10). Here, BIRC5 is linked to neuroblastoma.